eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors

PI3K-mammalian target of rapamycin and MAPK/ERK kinase (MEK)/mitogen-activated protein kinase (MAPK) are the most frequently dysregulated signaling pathways in cancer. A problem that limits the success of therapies that target individual PI3K-MAPK members is that these pathways converge to regulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijazi, Maruan, Casado, Pedro, Akhtar, Nosheen, Alvarez-Teijeiro, Saul, Rajeeve, Vinothini, Cutillas, Pedro R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184568/
https://www.ncbi.nlm.nih.gov/pubmed/35513296
http://dx.doi.org/10.1016/j.mcpro.2022.100240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184568/
https://www.ncbi.nlm.nih.gov/pubmed/35513296
http://dx.doi.org/10.1016/j.mcpro.2022.100240

Ejemplares similares